Nasdaq:CDXS
CODEXIS, INC.
A clinical-stage biotech firm engineering novel cell therapies for severe immune-mediated diseases, currently relying on equity financing to fund R&D amid declining revenues.
Key Metrics
Investment Thesis
Bull Case
If CDXS successfully advances its clinical candidates through pivotal trials, the value of its proprietary platforms could expand exponentially upon commercialization or successful licensing deals. Current depressed share prices may offer an entry point for investors willing to tolerate high risk for potential blockbuster asset discovery in the immunology space. The company's substantial paid-in capital and marketable securities provide a buffer against short-term volatility while building pipeline value.
Bear Case
The stock carries extreme downside risk given the negative net profit trend, declining revenue from $138.6M to $59.3M, and an inability to generate positive operating cash flow. Investors must worry about further dilution through share issuances as the company burns through its $20.8M cash reserves without a clear path to profitability. The widening gap between operating expenses and revenue suggests fundamental business model challenges that could lead to bankruptcy if external funding dries up.
About CODEXIS, INC.
CodeXis, Inc. (CDXS) is a clinical-stage biotechnology company focused on developing novel therapeutic candidates to treat severe immune-mediated diseases, primarily leveraging proprietary cell engineering platforms. The company operates within the specialized immunology and oncology sectors, utilizing its technology to create engineered T-cell therapies for patients with complex conditions. With significant investments in research and development alongside substantial common share issuances, CDXS aims to transition from clinical trials to commercialization while navigating a challenging cash position.
Analysis
Management Discussion
Management's recent financial performance reveals a severe deterioration in profitability, with net income dropping to -$65.3M and cash flow from operations turning deeply negative at -$49.4M. Despite generating gross profit of $43.1M, massive operating expenses of $101.6M and heavy R&D spending of $46.3M have eroded all earnings, while the net change in cash stands at -$45.9M. The reliance on capital expenditures and debt issuances to fund operations highlights a precarious balance sheet where current liabilities exceed current assets significantly.
Industry Overview
The biotechnology sector is characterized by high capital intensity, long development cycles, and binary outcomes where clinical failures can wipe out years of investment. Companies in this space often operate at a loss during the R&D phase, relying on venture capital, public markets, or grant funding to sustain operations until product approval. Regulatory hurdles remain steep, requiring extensive safety and efficacy data before therapies can reach patients.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $138.6M | $70.1M | $59.3M |
| Cost of Revenue | $38.0M | $12.8M | $16.3M |
| Gross Profit | $100.6M | $57.3M | $43.1M |
| Operating Expenses | $135.4M | $125.4M | $101.6M |
| Operating Income | $-34.9M | $-68.1M | $-58.5M |
| R&D | $80.1M | $58.9M | $46.3M |
| G&A | $52.2M | $53.2M | $55.1M |
| Stock-Based Comp | $14.5M | $10.0M | $13.1M |
| D&A | — | — | $4.9M |
| Depreciation | $5.4M | $5.5M | $4.8M |
| Other OpEx | $3.2M | $13.3M | $165.0K |
| Non-Operating Income | $1.6M | $-8.1M | $-6.7M |
| Interest Income | $1.4M | $4.2M | $3.7M |
| Pre-Tax Income | $-33.3M | $-76.2M | $-65.2M |
| Income Tax | $276.0K | $69.0K | $34.0K |
| Continuing Ops | $-33.6M | $-76.2M | $-65.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-33.6M | $-76.2M | $-65.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-33.6M | $-76.2M | $-65.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $162.9M | $93.5M | $98.8M |
| Cash & Equivalents | $114.0M | $65.1M | $19.3M |
| Marketable Securities | — | — | $54.2M |
| Accounts Receivable | $31.9M | $10.0M | — |
| Inventory | $2.0M | $2.7M | $1.8M |
| Prepaid Expenses | $5.5M | $5.2M | $4.1M |
| Other Current Assets | $9.5M | $10.4M | $19.4M |
| Long-Term Assets | $87.5M | $43.1M | $50.2M |
| PP&E (Net) | $22.6M | $15.5M | $14.2M |
| Goodwill | $3.2M | $2.5M | $2.5M |
| Operating Leases | $39.3M | $13.1M | $28.7M |
| Other LT Assets | $22.4M | $12.0M | $4.9M |
| Total Assets | $250.4M | $136.6M | $149.0M |
| Current Liabilities | $49.1M | $35.8M | $23.6M |
| Accounts Payable | $3.2M | $5.9M | $2.8M |
| Current Leases | $5.4M | $10.1M | $2.8M |
| Deferred Revenue | $13.7M | $3.8M | $350.0K |
| Other Current Liab | $11.5M | $11.2M | $11.4M |
| Long-Term Liabilities | $56.5M | $14.1M | $58.4M |
| Long-Term Debt | — | — | $28.9M |
| LT Operating Leases | $38.3M | $12.2M | $28.2M |
| Other LT Liab | $1.4M | $1.2M | $1.3M |
| Total Liabilities | $105.6M | $49.9M | $82.1M |
| Shareholders' Equity | $144.8M | $86.6M | $66.9M |
| Paid-In Capital | $566.1M | $584.1M | $629.7M |
| Retained Earnings | $-421.3M | $-497.5M | $-562.8M |
| AOCI | — | — | $52.0K |
| Total L&E | $250.4M | $136.6M | $149.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-33.6M | $-76.2M | $-65.3M |
| Non-Cash Adjustments | $15.5M | $65.2M | $35.9M |
| Working Capital Changes | $29.4M | $-41.6M | $-20.1M |
| Cash from Operations | $11.3M | $-52.6M | $-49.4M |
| Capital Expenditures | $8.3M | $4.4M | $4.3M |
| Cash from Investing | $-13.6M | $-4.9M | $-57.0M |
| Debt Issuances | — | — | $29.5M |
| Cash from Financing | $-575.0K | $8.2M | $60.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-2.9M | $-49.3M | $-45.9M |
| Beginning Cash | $118.9M | $116.0M | $66.7M |
| Ending Cash | $116.0M | $66.7M | $20.8M |
Frequently Asked Questions
How does CODEXIS, INC. make money?
The company's revenue streams are primarily derived from grants, government funding, and licensing agreements related to its proprietary cell engineering platforms, as evidenced by low cost of revenue relative to operating expenses and high non-cash adjustments. Revenue has shifted away from traditional product sales to reliance on external funding sources, indicating a pre-commercialization stage where R&D spending dominates the P&L.
What are the main risks for CDXS?
The company faces an immediate liquidity crisis with negative operating cash flow and a significant retained earnings deficit, necessitating further dilutive equity financing. Revenue has contracted sharply over the last three years, indicating potential product-market fit issues or loss of key grant funding. High R&D and general administrative expenses suggest a burning rate that outpaces current cash reserves without new capital injections.
What is CDXS's competitive advantage?
CodeXis possesses unique proprietary cell engineering platforms that differentiate its therapeutic candidates in the crowded immunology market. The company's specialized technology stack offers potential for high-value licensing deals or strategic partnerships if clinical milestones are achieved. Its focus on severe immune-mediated diseases targets unmet medical needs where few alternatives currently exist.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.